Response to: Eculizumab package insert recommendations for meningococcal vaccinations: Call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder

Sean J. Pittock, Ilene Weitz, James F. Howard, Guido Sabatella, Sunil Mehta, Jeremy Franklin

Research output: Contribution to journalArticle

Abstract

We thank Avasarala et al for their editorial on meningococcal infection prevention in patients with neuromyelitis optica spectrum disorder (NMOSD) receiving eculizumab. While we appreciate the Authors' concerns and agree that its manufacturers (Alexion) have a responsibility to promote optimal patient safety, it iscritical that clinicians treating patients with eculizumab adhere to the latest vaccination recommendations, consider individual risk profiles, and monitor patients for early signs of meningococcal disease.

Original languageEnglish (US)
JournalCNS Spectrums
DOIs
StateAccepted/In press - 2020

Keywords

  • Eculizumab
  • Meningoccocal infection
  • Nmosd
  • Prevent
  • Safety
  • Vaccination protocol

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Response to: Eculizumab package insert recommendations for meningococcal vaccinations: Call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder'. Together they form a unique fingerprint.

  • Cite this